No Data
No Data
No Data
No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
BenzingaApr 30 06:31 ET
Aquestive Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 141.94% HC Wainwright & Co. → $9 Reiterates Buy → Buy 04/11/2024 168.82% Piper Sandler → $10 In
BenzingaApr 30 06:30 ET
Aquestive Therapeutics Earns Buy Rating on Libervant's Pediatric Approval and Anaphylm's Market Potential
TipRanksApr 30 06:18 ET
Aquestive Stock Falls Amid Libervant Approval, Anaphylm Update
Seeking AlphaApr 29 13:56 ET
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
Aquestive Therapeutics (AQST) said Monday that the US Food and Drug Administration has approved Libervant Buccal Film to treat intermittent, stereotypic episodes of frequent seizure activity, which ar
MT NewswiresApr 29 11:19 ET
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers
Seeking AlphaApr 29 10:02 ET
Mod Tan : i have encounter before with other FDA approve and the stock dip 25% and in about 2-3 weeks it shot back up and its time to close positions. Just don't panic. The stock was shorted.
Mod Tan : There was a stock ticker ccxi and before FDA approve many people who did stop loss got caught off guard from 22 went down to 12 and immediately shot back up to 23. The stock was then halted pending FDA announcement. After FDA approve it when up 35-39.
70686049 Mod Tan: This. $Day One Biopharmaceuticals (DAWN.US)$ a perfect example.
No Data
No Data